Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gene therapy may free Beta-Thalassemia patients from lifelong transfusions

NCT ID NCT06308159

First seen Jan 04, 2026 · Last updated May 24, 2026 · Updated 23 times

Summary

This early-stage study tests a one-time gene therapy for people with a severe form of beta-thalassemia that requires regular blood transfusions. The treatment uses the patient's own blood stem cells, which are modified in a lab to produce healthy hemoglobin. The goal is to see if this therapy can raise hemoglobin levels enough to reduce or stop the need for transfusions. Six participants will be enrolled and followed for safety and effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BETA-THALASSEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

    RECRUITING

    Kunming, Yunnan, 650100, China

    Contact Email: •••••@•••••

  • Kunming Hope of Health Hospital

    RECRUITING

    Kunming, Yunnan, 650200, China

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.